BIO News and Press, Bio-Rad Laboratories Inc. Class A From 11/04/22

Eisai's Sales Subsidiary Collaborates with Thai Life Insurance to Support Access to Treatments for Dementia, Including Alzheimer's Disease, in Thailand TOKYO, Nov 4, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today that its Thai sales subsidiary Eisai (Thailand) Marketi...

Eisai Satisfies All-case Study Requirement for Antiepileptic Agent Inovelon TOKYO, Nov 2, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has received notification from Japan's Ministry of Health, Labour, and Welfare (MHLW) that the "all-case study" specified p...

Eisai Announces Plans to Submit Application for Partial Change to Label for Dosage and Administration of Aricept for Treatment of Dementia with Lewy Bodies Based on Results of Drug Reexamination TOKYO, Nov 2, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has ...

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced that the company’s management will participate in a Fireside Chat event during the Credit Suisse 31 st Annual Healthcare Conference on T...

Summary The FDA is working with congress to extend its regulatory arm over the gene testing market. Veracyte's products are marketed as LDTs and are not approved by the FDA. Regulatory risk weighs against Veracyte's relatively low cash burn and robust balance sheet, underpinni...

Bio-Rad Laboratories, Inc. (BIO) Q3 2022 Earnings Conference Call October 27, 2022, 17:00 ET Company Participants Edward Chung - VP, IR Ilan Daskal - EVP & CFO Andrew Last - EVP & COO Norman Schwartz - Chairman, CEO & President Dara Wright - E...

Bio-Rad Labs press release ( NYSE: BIO ): Q3 Non-GAAP EPS of $2.60 misses by $0.17 . Revenue of $680.8M (-8.9% Y/Y) misses by $1.9M . For the full-year 2022, the company continues to anticipate non-GAAP currency-neutral revenue growth to be at the high end of t...

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced financial results for the third quarter ended September 30, 2022. Third-quarter 2022 net sales were $680.8 million, a decrease of 8.9 percent c...

Malaysian Genomics Signs Strategic Collaboration Agreement for Expansion in the UAE United Arab Emirates (UAE), Oct 26, 2022 - (ACN Newswire) - Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155), a leading genomics and biopharmaceutical specialist, today announced t...

Clinical Research Opportunities in China and the Path to USFDA Approval - Whitepaper SYDNEY, AU, Oct 25, 2022 - (ACN Newswire) - Novotech, the leading Asia Pacific biotech specialist CRO, and GlobalData have published the latest China biotech landscape analysis with expert gui...